Rana Elmesseri - AIMS@JCU

Rana Elmesseri

rana.elmesseri@my.jcu.edu.au

PhD
College of Medicine and Dentistry

Rana Elmesseri

rana.elmesseri@my.jcu.edu.au

PhD
College of Medicine and Dentistry
Interaction between the mushroom coral Heliofungia and its microbial symbionts: Endozoicomonas, the heliomacins and CAMAs

A dedicated PhD candidate at the College of Medicine and Dentistry, James Cook University, with strong pharmaceutical and microbiological expertise developed through academic and professional experience at Misr International University and JCU. Holds a Pharmacy degree and an MPhil in Pharmaceutical Sciences. Passionate about microbiology, marine ecology, and biomedical research.

Interaction between the mushroom coral Heliofungia and its microbial symbionts: Endozoicomonas, the heliomacins and CAMAs

2024 to 2028

Project Description

Studying the coral microbiome and its immune defences is crucial for advancing our understanding of coral health and resilience, yet these areas remain underexplored. Research into antimicrobial peptides (AMPs) has been limited, particularly regarding their roles in coral immunity. Recently, a new homolog of hydramacin, an AMP originally reported from Hydra, was discovered in the coral Heliofungia actiniformis. Investigating this peptide’s antimicrobial properties and its influence on coral-associated microbial aggregates (CAMAs) could unravel novel mechanisms of coral defence and interactions with their microbiomes. This research is essential for developing strategies to mitigate coral disease and improve conservation efforts in the face of global stressors.

Project Importance

This project not only advances our understanding of how coral-associated bacteria like Endozoicomonas contribute to Heliofungia’s immune defences but also builds on our discovery of a novel antimicrobial peptide (AMP) with potential activity against coral and human pathogens. This highlights the dual ecological and biomedical value of the Heliofungia microbiome, paving the way for nature-inspired antimicrobial solutions while informing coral conservation

Project Methods

1. Sampling and DNA extraction
A total of 10 Heliofungia coral individuals will be collected from the Coral Sea, Australia, 5 of which are wild individuals from Orpheus Island and the other 5 are captive individuals at AIMS to study the intra-specific variability of coral microbiome between captive and wild individuals. Two tentacles will be collected and dissected from each coral individual with 2-3 replicates at different time intervals for possible seasonal effects.
Total DNA extractions will be carried out using a modified CTAB method. The bacterial 16S rRNA gene will be amplified using a universal primer pair: 27F (5’-AGAGTTTGATCMTGGCTCAG-3’) and 1492R (5’- GTTACCTTGTTACGACTT-3’). In parallel, Endozoicomona-specific primers for Endozoicomonas will be used: En154F (5’- ATAGCCCGGAGAAATCCG-3’) and En771R (5’-TCAGTGTCARRCCTGAGTGT-3’).

PCR will be performed, and target PCR products will be recovered by ethanol.

2. Miseq sequencing
DNA-tagging PCR will be then carried out following the protocol in Chen et al. (2011). Equal amounts of tagged PCR products for all tissue samples will be pooled as 2 libraries and submitted for 2 x 250 bp pair-end Illumina MiSeq sequencing, performed by Yourgene Bioscience (Taipei, Taiwan). The resulting sequences will be analysed using Microbiome Analyst (microbiomeanalyst.ca) by reference to the latest versions of the bacterial 16S sequence databases, and then compared to the data gathered by our collaborator Sin-ling Tang from 10 Indonesian Heliofungia individuals, adopting the same sampling criteria and methodology as mentioned under the previous section.


3. Production of recombinant Heliomacin Proteins
3.1 Cloning Procedure
Sequences encoding the Heliomacins will be cloned into the expression vector PIM050 and transformed into the Escherichia coli strain BL21 (DE3) RIPL. Other E. coli strains may be transformed if efficient expression requires this. For example, Origami™ 2 host strains can be used which greatly enhance disulfide bond formation for recombinant proteins that further encourages proper protein folding.
3.2 Expression
Recombinant Heliomacins will be expressed in the E. coli strain BL21 (DE3) RIPL in Terrific broth with 100 g/ml ampicillin and 50 g/ml chloramphenicol. In 1L culture flasks, 100 ml media with 4 mM glucose and 0.4 mM galactose will be inoculated with a full inoculation loop of bacteria scraped from an overnight Luria broth agar with 100 g/ml ampicillin and 50 g/ml chloramphenicol master plate. The cultures will be incubated at 37 oC with shaking at 250 RPM until log phase is reached, then reduced to 16 oC for 72 hours.
3.3 Extraction and purification of mature Heliomacin peptides
After expression, bacteria will be harvested by centrifugation and resuspended in phosphate-buffered saline containing 200 mM Imidazole. Next, cell lysis will take place under high pressure using French Press. Pellet resuspension will be tried out using different buffers/detergents to get a soluble protein. For example, we will try Plain PBS, Triton X-100, B-Per, 20% glycerol, Sarcosine and BugBuster®. If the protein turns out to be insoluble, the pellets will be dissolved in a denaturing buffer (6 M guanidine hydrochloride, 50 mM Tris, pH 7.2) and incubated at 20 °C overnight. Mature Heliomacin will then be purified using NI-charged resin Profinity IMAC, refolded and dialysed.
4. Investigating the antimicrobial activity of Heliomacin
4.1 Determination of Minimum Bactericidal Concentration (MBC) for Heliomacin

The antimicrobial activity of Heliomacin will be investigated as previously described by Dingley et al, (2008). Briefly, test strains will be grown in brain heart infusion broth at 37 °C for 2–3 h. The cells will be washed 3 times in 10 mM sodium phosphate buffer, pH 7.4, supplemented with 1% tryptic soy broth, and the cell number will be adjusted to 104-105 cells/ml. From the prepared cell suspension, 100 µl will be mixed with 10 µl of Heliomacin dissolved in 10 mM sodium phosphate buffer, pH 7.4, and incubated at 37 °C. After 2 h of incubation, the colony forming units will be determined. Antimicrobial activity will be tested for the microbial strains by determination of LD90 (90% lethal dose) or minimal bactericidal concentrations (MBCs) (~99.9% killing).
Bacterial strains proposed are coral derived strains as; Endozoicomonas montiporae, Vibrio corallilyticus and other coral associated bacterial isolates, as well as medically relevant pathogens as; Escherichia coli, Staphylococcus aureus and Klebsiella pneumoniae.
4.2 Determination of minimum Inhibitory concentrations (MIC)
The antimicrobial activity could also be determined by Agar diffusion method as illustrated by Hudzicki, (2009). Briefly, Agar plates will be inoculated with each of the bacterial strains then filter strips/ discs with known concentrations of the peptides will be placed on the agar plates. After incubation, the MIC value can later be determined from the relationship between the size of growth inhibition zones and the peptide concentration.

4.3 Assay for Permeabilization of Bacterial Membranes
Membrane Permeabilization assays will be performed to determine the mechanism by which Heliomacin kills microbes. Bacteria with compromised membranes will be detected by monitoring the fluorescence of the DNA binding dye SYTOX Green (Invitrogen) as previously described by Herbst et al (2002).


4.4 Green Fluorescent Protein (GFP) Tag to test for bacterial aggregation in vitro
GFP possesses several attributes that make it valuable for localization studies, chiefly its capacity to fluoresce when attached to target polypeptides, without requiring external substrates [53]. GFP cloning and expression will be performed along with Heliomacin as a fusion protein.
5. Investigating the physical characteristics of the generated peptides
The thermal stability of the generated recombinant peptides will be evaluated using the GFP-Basta S method as described by Morgane et al (2010). This protocol will also be utilized to draw conclusions on the peptides pH and salt sensitivities, as well as determine their thermal aggregation profiles.


6. Determining the location of CAMAs within Heliofungia tentacles

6.1 Fluorescence in situ hybridization (FISH)
In situ localization of CAMAs will be conducted according to the protocol detailed in Wada et al (2016). Briefly, coral tissue sections will be dewaxed in xylene, dehydrated briefly once in 100% ethanol and dried completely. The dried sections will be immersed in a 0.2 M HCl solution for 12 min, followed by a 20 mM Tris-HCl solution (pH 8.0) for 10 min at room temperature. The sections will be mounted with proteinase K (50 μg ml−1) in 20 mM Tris-HCl solution at 37 °C for 5 min for bacterial cell wall permeabilization, and washed in a 20 mM Tris-HCl solution at room temperature for 10 min. Oligonucleotide probes, including a probe targeting the 16S rRNA gene (EUB338mix: 5′-GCWGCCWCCCGTAGGWGT-3′) and a nonsense, negative control probe (Non338: 5′-ACATCCTACGGGAGGC-3′), will be labeled with the Cy3 fluochrome. Tissue sections will be covered with hybridization buffer (30% v/v formamide, 0.9 M NaCl, 20 mM Tris-HCl [pH 8.0], 0.01% SDS), then each oligonucleotide probe will be added to each serial section. After incubation, sections will be washed and air dried completely. The dried sections will be mounted in an antifade mounting medium Fluoromount/Plus. Sections will be examined and recorded using a FV1000-D confocal microscope (Olympus, Japan). Non-specific probe binding in tissue sections will be identified as detailed by Wada et al (2016).

Specific detection of bacteria by FISH can be problematic for coral samples due to nonspecific binding of probes and background autofluorescence of granular cells and nematocysts. Therefore, CAMAs will be identified by their characteristic shapes, in addition to fluorescent signals bound by the general bacteria-targeted probe set EUB338mix and comparisons to background autofluorescence and non-specific binding (using Non338 probe).



7. Generation of Heliomacin protein antibodies and immunolabelling sections of Heliofungia sp. to co-localize Heliomacin and CAMAs

7.1 Immunohistochemical assay


Heliomacin peptides will be used for the immunization procedure of chickens. Polyclonal antibodies to the recombinant Heliomacin peptides will be produced by an immunization procedure using chickens. The produced antibodies will then be purified using an IgY column (HiTrap).

Project Results

The AMP heliomacin has successfully been designed and expressed as recombinant protein. the antimicrobial activity of heliomacin is currently being tested against a broad range of coral pathogenic bacteria. the bacterial growth had significantly decreased by increasing the concentrations of heliomacin when performing antimicrobial assays. Similar results have been found with E. coli. this is prompting us to investigate heliomacin's antimicrobial potential on a wider range of human pathogens along with other ecologically relevant strains as an approach to combat the rising rates of antimicrobial resistance.
Interestingly, the infamous Heliofungia symbiont Endozoicomonas growth was not detrimentally affected by heliomacin compared to pathogenic strains.
CAMAs have been clearly visualised with H&E stain in Heliofungia tentacles. the next step should be CLSM and immunohistochemical assays to co-locate heliomacin with CAMAS.

Keywords

Bacteria,
Controlled Environment,
Coral reefs,
Corals,
Ecology,
Interaction,
Microbial,
Microbiology,
Qualitative techniques,
Quantitative marine science